<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631007</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx180.005</article-id><article-id pub-id-type="publisher-id">ofx180.005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Late Breaker Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Ethanol Lock Treatment and Secondary Prophylaxis for Central Line-Associated Bloodstream Infection in Pediatric Hematology and Oncology: A&#x000a0;Randomized, Double-Blind, Placebo-Controlled, Intervention Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wolf</surname><given-names>Joshua</given-names></name><degrees>MBBS FRACP</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Connell</surname><given-names>Tom</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Allison</surname><given-names>Kim J</given-names></name><degrees>BSN</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Li</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>Julie</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Branum</surname><given-names>Kristen</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Borello</surname><given-names>Eloise</given-names></name><degrees>BNSc</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Gaur</surname><given-names>Aditya</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Hakim</surname><given-names>Hana</given-names></name><degrees>MD, MS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Yin</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Mechinaud</surname><given-names>Francoise</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Hayden</surname><given-names>Randall</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Monagle</surname><given-names>Paul</given-names></name><degrees>MBBS, MD</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Worth</surname><given-names>Leon</given-names></name><degrees>MBBS</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Curtis</surname><given-names>Nigel</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Flynn</surname><given-names>Patricia M</given-names></name><degrees>MD, MS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Infectious Diseases, St. Jude Children&#x02019;s Research Hospital</institution>, <addr-line>Memphis, Tennessee;</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Clinical Paediatrics, Murdoch Children&#x02019;s Research Institute</institution>, <addr-line>Parkville</addr-line>, <country>Australia;</country></aff><aff id="AF0003">
<label>3</label>
<institution>St. Jude Children&#x02019;s Research Hospital</institution>, <addr-line>Memphis, Tennessee;</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Biostatistics, St. Jude Children&#x02019;s Research Hospital</institution>, <addr-line>Memphis, Tennessee</addr-line>;</aff><aff id="AF0005">
<label>5</label>
<institution>Pharmaceutical Sciences, St. Jude Children&#x02019;s Research Hospital</institution>, <addr-line>Memphis, Tennessee</addr-line>;</aff><aff id="AF0006">
<label>6</label>
<institution>Oncology, Royal Children&#x02019;s Hospital Melbourne</institution>, <addr-line>Parkville, Victoria</addr-line>, <country>Australia</country>;</aff><aff id="AF0007">
<label>7</label>
<institution>Oncology, Royal Childrens Hospital Melbourne</institution>, <addr-line>Parkville, Victoria</addr-line>, <country>Australia</country>;</aff><aff id="AF0008">
<label>8</label>
<institution>Hematology, Royal Children&#x02019;s Hospital Melbourne</institution>, <addr-line>Parkville, Victoria</addr-line>, <country>Australia</country>;</aff><aff id="AF0009">
<label>9</label>
<institution>Peter MacCallum Cancer Ctr.</institution>, <addr-line>Melbourne</addr-line>, <country>Australia</country></aff><aff id="AF0010">
<label>10</label>
<institution>Department of Paediatrics, The University of Melbourne</institution>, <addr-line>Parkville</addr-line>, <country>Australia</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 228. Late Breaker Oral Abstracts</p><p>
<italic>Saturday, October 7, 2017: 10:30 AM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S735</fpage><lpage>S736</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx180.005.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Central line-associated bloodstream infection (CLABSI) commonly affects children with cancer and hematological disorders, with significant attributable costs and morbidity. Treatment failure, comprising persistent infection, infection relapse or new infection, occurs in ~50% of cases. Adjunctive ethanol lock therapy (ELT) has been proposed to prevent failure, but has never been tested in a prospective controlled&#x000a0;study.</p></sec><sec id="s2"><title>Methods</title><p>A&#x000a0;prospective, dual-center, double-blind, block-randomized, placebo-controlled trial of ELT (70% ethanol in water) for CLABSI, given as treatment (2 hours per lumen per day) for 5&#x000a0;days, followed by secondary prophylaxis (2 hours per lumen up to 3&#x000a0;days per week) for 24 weeks, in children with oncologic or hematologic disorders (NCT01472965). Risk of treatment failure was compared between intervention and control groups according to proportional and cumulative incidence models, using intention-to-treat and per-protocol analyses. The study was discontinued at a pre-specified futility analysis.</p></sec><sec id="s3"><title>Results</title><p>Of 94 evaluable participants, 48 were randomized to ELT and 46 to placebo; groups were similar at baseline for all measured variables. Forty-one (43.6%) participants had treatment failure (11 early failure, 9 relapse, and 21 reinfection). There was no difference between patients receiving ELT or placebo for risk of treatment failure (43.8% vs. 43.5%; <italic>P =</italic> 0.9) or for cumulative incidence of treatment failure in intention to treat (Figure&#x000a0;1) and per-protocol analyses (Figure&#x000a0;2). Catheter occlusion was significantly more common in participants receiving ethanol (58.3% vs. 32.6%, <italic>P =</italic> 0.01) but other adverse events, including LFT elevations (14.6% vs. 26.1%) and infusion reactions (18.8% vs. 8.7%), were not significantly different between groups.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx180_IF002"/></fig><fig fig-type="figure" id="F2" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx180_IF003"/></fig></sec><sec id="s4"><title>Conclusion</title><p>Although observational studies suggested ELT might be effective for treatment of CLABSI in pediatric oncology, we found no benefit in treatment outcome and an increase in adverse effects. These results may not apply to patients receiving dialysis or with fungal CLABSI as these were not well-represented. Routine use of ELT for CLABSI in children with oncologic or hematologic disorders is not recommended.</p></sec><sec id="s5"><title>Disclosures</title><p>All authors: No reported disclosures.</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>